UNSPSC 51182013: Stanozolol

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4R1VB9P8V3, chemically known as 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol but generally known as stanozolol, which bears US NIH Compound Identifier 25249. European Medicines Agency schedules Stanozolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10641MIG.

UNSPSC 51182013 Stanozolol is a Commodity code capturing pharmaceutical products, specifically anabolic steroids and controlled substances that state and local governments procure through multistate cooperative purchasing vehicles. The recent activity shows procurement is driven by multistate cooperative groups aggregating demand across participating state agencies, counties, and other public entities to obtain volume pricing and standardized sourcing for pharmaceutical inventories. The scope of work involves supplying finished pharmaceutical products with certified compliance to cGMP and DSCSA requirements, detailed product specification data including NDC codes and packaging configurations, and maintaining established relationships with authorized wholesale distributors operating chargeback systems. Issuing bodies include state departments of administration and procurement offices that manage cooperative purchasing alliances on behalf of multiple member jurisdictions; the MMCAP structure distributes contracts to authorized wholesalers rather than directly to end-user agencies, which then access products through those distributors at negotiated pricing tiers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The RFP covers participating state and local facilities across Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation emphasizes price competitiveness (75 percent) and supports multiple pricing formats including flat price, net price (NF30, NF60, NF90), and WAC-minus structures. Vendors must carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, certify FDA compliance, and agree to a 3 percent administrative fee with performance penalties ranging from $200 to $1,500 per violation. Award values are not disclosed; the contract term is two years for new responders with optional extensions, and awarded vendors will be provided to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026.